When you enter multiple keywords separated by space, your search will contain results that match any of the keywords (OR search).
  • 41 Hits
  • Search Condition : Filter (MeSH = Lung Neoplasms / drug therapy)
Species Resource Title
Human and Animal Cells A549(RCB0098) In vitro evaluation of the cellular effect of indium tin oxide nanoparticles using the human lung adenocarcinoma A549 cells.
DNA material CSII-CMV-MCS-IRES2-Bsd (RDB04385) , CS-RfA-EVBsd (RDB06090) , pCMV-VSV-G-RSV-Rev (RDB04393) , pCAG-HIVgp (RDB04394) Arl4c expression in colorectal and lung cancers promotes tumorigenesis and may represent a novel therapeutic target.
Human and Animal Cells PC-14(RCB0446) Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice.
Human and Animal Cells Ba/F3 Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.
Human and Animal Cells Ba/F3 Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.
Human and Animal Cells A549 Trehalose Liposomes Suppress the Growth of Tumors on Human Lung Carcinoma-bearing Mice by Induction of Apoptosis In Vivo.
Human and Animal Cells LLC(RCB0558) Gas6 derived from cancer-associated fibroblasts promotes migration of Axl-expressing lung cancer cells during chemotherapy.
Human and Animal Cells PC-9(RCB4455) Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.
Human and Animal Cells PC-9(RCB4455) Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.
Human and Animal Cells A549(RCB0098) Anticancer effects of novel thalidomide analogs in A549 cells through inhibition of vascular endothelial growth factor and matrix metalloproteinase-2.
Human and Animal Cells LC-2/ad(RCB0440) Loss of YAP1 defines neuroendocrine differentiation of lung tumors.
Human and Animal Cells PC-9(RCB4455) The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation.
Human and Animal Cells Ba/F3(RCB0805) , LC-2/ad(RCB0440) Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
Human and Animal Cells B901L(RCB3530) MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells.
Human and Animal Cells SSP-25(RCB1293) Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo.
Human and Animal Cells Ba/F3(RCB0805) Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma.
Human and Animal Cells PC-9(RCB4455) Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.
Human and Animal Cells Ba/F3(RCB0805) Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.
Human and Animal Cells WEHI-3(RCB0035) , Ba/F3 Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.
Human and Animal Cells A549 Caffeic acid phenethyl ester down-regulates claudin-2 expression at the transcriptional and post-translational levels and enhances chemosensitivity to doxorubicin in lung adenocarcinoma A549 cells.